PLoS ONE · 2014 · 10 citations · 27 references
Veterinary MedicineBiotechnologyImmunologyImmunizationImmunopathologyVaccinologyAdaptive Immunity To ParasitesDna VaccinesT-cell Responses To ParasitesVaccinationVaccine DeliveryVaccine-preventable DiseasesDeoxyribonucleic Acid (Dna) VaccineGlutathione S-transferase ActivityImmunopathology Of SchistosomiasisMechanisms Of Vaccine-induced ProtectionPlasmid Dna Vaccine DesignPlasmid Vaccine VectorsSchistosoma-specific T Cell ResponsesVaccine Candidate Antigens
In order to explore the high performance bivalent DNA-based vaccine against schistosomes, SjFABP and Sj26GST were selected and used to construct a vaccine. Two strategies were used to construct the bivalent DNA vaccine. In the first strategy, a plasmid encoding antigen in the secreted form was used, while in the other, a plasmid encoding a truncated form of SjFABP and Sj26GST targeted to the cell surface was used. Various parameters, including antibody and cytokine response, proliferation, histopathological examination, and characterization of T cell subsets were used to evaluate the type of immune response and the level of protection against challenge infection. Injection with secreted pIRES-sjFABP-sj26GST significantly increased the levels of antibody, splenocyte proliferation, and production of IFN-γ, compared with membrane-anchored groups. Analysis of splenic T cell subsets showed that the secreted vaccine significantly increased the percentage of CD3(+)CD4(+) and CD3(+)CD8(+) T cells. Liver immunopathology (size of liver granulomas) was significantly reduced in the secreted group compared with the membrane-anchored groups. Moreover, challenge experiments showed that the worm and egg burdens were significantly reduced in animals immunized with recombinant vaccines. Most importantly, secreted Sj26GST-SjFABP markedly enhanced protection, by reducing worm and egg burdens by 31.8% and 24.78%, respectively, while the membrane-anchored group decreased worm and egg burdens by 24.80% and 18.80%, respectively. Taken together, these findings suggest that the secretory vaccine is more promising than the membrane-anchored vaccine, and provides support for the development and application of this vaccine.
27
A. Sher, Robert L. Coffman, Sara Hieny et al. · Proceedings of the National Academy of Sciences · 1990 · 235 citations
Fernanda C. Cardoso, Gilson Costa Macedo, Elisandra Gava et al. · PLoS neglected tropical diseases · 2008 · 185 citations · Full text